Meros Investment Management LP Grows Stock Holdings in Harvard Bioscience, Inc. (NASDAQ:HBIO)

Meros Investment Management LP grew its stake in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) by 1.6% during the 2nd quarter, HoldingsChannel reports. The fund owned 835,213 shares of the medical instruments supplier’s stock after buying an additional 13,421 shares during the period. Meros Investment Management LP’s holdings in Harvard Bioscience were worth $2,380,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. AMH Equity Ltd raised its stake in shares of Harvard Bioscience by 7.5% during the 1st quarter. AMH Equity Ltd now owns 2,324,200 shares of the medical instruments supplier’s stock valued at $9,855,000 after purchasing an additional 161,307 shares during the period. Assenagon Asset Management S.A. increased its position in shares of Harvard Bioscience by 193.9% during the second quarter. Assenagon Asset Management S.A. now owns 227,701 shares of the medical instruments supplier’s stock valued at $649,000 after buying an additional 150,218 shares during the period. Acuitas Investments LLC lifted its holdings in shares of Harvard Bioscience by 24.8% in the second quarter. Acuitas Investments LLC now owns 407,343 shares of the medical instruments supplier’s stock worth $1,161,000 after buying an additional 80,827 shares in the last quarter. Corsair Capital Management L.P. bought a new position in shares of Harvard Bioscience in the fourth quarter valued at approximately $356,000. Finally, Vanguard Group Inc. grew its stake in Harvard Bioscience by 2.4% during the first quarter. Vanguard Group Inc. now owns 2,152,147 shares of the medical instruments supplier’s stock valued at $9,125,000 after acquiring an additional 49,576 shares in the last quarter. 80.87% of the stock is owned by institutional investors.

Harvard Bioscience Stock Performance

NASDAQ HBIO opened at $2.66 on Friday. The company’s 50 day simple moving average is $2.94 and its two-hundred day simple moving average is $3.33. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.05 and a quick ratio of 0.94. Harvard Bioscience, Inc. has a 1 year low of $2.50 and a 1 year high of $5.56. The stock has a market capitalization of $115.52 million, a PE ratio of -13.30 and a beta of 1.30.

Harvard Bioscience (NASDAQ:HBIO) last posted its earnings results on Thursday, August 8th. The medical instruments supplier reported ($0.03) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.06). The business had revenue of $23.10 million for the quarter, compared to analysts’ expectations of $29.91 million. Harvard Bioscience had a negative return on equity of 2.70% and a negative net margin of 10.56%. Analysts predict that Harvard Bioscience, Inc. will post 0.11 earnings per share for the current fiscal year.

Harvard Bioscience Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.